Table 2.
Immune Cell Subset | Changes in Frequency | Changes in Phenotype | Reference | |
---|---|---|---|---|
CD4+/CD8+ T Cell Ratio | Increased ratio indicates poor efficacy after treatment | 20,21,126 | ||
CD8+ T Cell | Mild | Decreased total number in the peripheral blood. Increased CD8+ T cells infiltrate the lungs with clonal expansion. In mild cases, multi-cytokine production of CD8+ T cells is higher compared to CD4+ T cells |
Upon SARS-CoV-2 infection, the circulating peripheral CD8+ T cells are activated and produce granzyme B and perforin. In convalescent patients, CD8+ T cells recognize the viral spike protein, M protein, and least eight SARS-CoV-2 ORFs |
8,21,61,68,88,102,127–134 |
Severe | Further decreased total number | Circulating peripheral CD8+ T cells are activated and produce high amounts of granzyme B and perforin, yet may exhibit increased expression of exhaustion markers, including PD-1, Tim-3, and NKG2A | 20,21,61,127–129 | |
CD4+ T Cell | Mild | Decreased total number. Decreased Treg, memory, and effector memory cells SARS-CoV-2 infection can prime CD4+ T lymphocytes to differentiate into Th17 and TFH. |
Decreased conventional Th1 and IFNγ secretion Increased pathogenic Th1 cells, which can secrete IL-6 and GM-CSF to induce CD14+ CD16+ monocyte activation Decreased CD4+ naïve, CD4+ memory, and effector memory subsets Increased CD4+ effector-GNLY subsets |
21,56,102,122,124,129–131,135–141 |
Severe | Decreased in the most severe cases and increased percentage of over-activated with reduced IFNγ production Increased percentage in the naive subset but decreased in the memory and effector memory subsets. Numbers increase with recovery |
Increased CD4+ naïve subsets Decreased CD4+ memory, and effector memory subsets CD4+ T lymphocytes differentiate into pathogenic Th1 cells. Increased CD4+ effector-GNLY subsets |
20,72,124,128,135,142 | |
Others T cell | Decreased numbers of total circulating γδT cells but increased frequency of CD4+ γδT cells | 143–145 | ||
B cell | Mild | The humoral response is less affected by the virus. Most convalescent COVID-19 individuals have neutralizing antibodies B cells in geminal center are largely absent during the acute phase |
Within 1 week of illness onset, antibodies are detectable in approximately 40% of patients. Fifteen days after infection, the detectable antibody count rapidly increases to 100%, followed by IgM (94.3%) and IgG (79.8%) Specific antibodies against the RBD of the spike protein, SARS-CoV-2 NP, and the main protease Increased active state but decreased memory B cell subsets |
20,72,124,127,131,135,146–155 |
Severe | Proportion of B cells is significantly higher than in moderate cases |